Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 3.8%

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s stock price fell 3.8% on Thursday . The stock traded as low as $9.33 and last traded at $9.33. 463,141 shares traded hands during trading, a decline of 92% from the average session volume of 5,898,366 shares. The stock had previously closed at $9.70.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on RXRX. Needham & Company LLC restated a “buy” rating and set a $17.00 price target on shares of Recursion Pharmaceuticals in a report on Friday, May 10th. KeyCorp raised their price target on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Monday, March 4th.

Recursion Pharmaceuticals Price Performance

The firm has a fifty day moving average of $8.73 and a 200 day moving average of $9.87.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.04. Recursion Pharmaceuticals had a negative return on equity of 79.96% and a negative net margin of 765.90%. The company had revenue of $13.80 million during the quarter, compared to the consensus estimate of $11.10 million. During the same period last year, the company earned ($0.34) EPS. Recursion Pharmaceuticals’s revenue for the quarter was up 14.0% on a year-over-year basis. On average, analysts predict that Recursion Pharmaceuticals, Inc. will post -1.6 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Recursion Pharmaceuticals news, CEO Christopher Gibson sold 50,000 shares of the business’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $7.73, for a total transaction of $386,500.00. Following the completion of the sale, the chief executive officer now directly owns 863,524 shares in the company, valued at approximately $6,675,040.52. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other Recursion Pharmaceuticals news, CFO Michael Secora sold 23,124 shares of the business’s stock in a transaction dated Wednesday, April 17th. The stock was sold at an average price of $7.58, for a total transaction of $175,279.92. Following the completion of the sale, the chief financial officer now directly owns 1,231,055 shares in the company, valued at approximately $9,331,396.90. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Christopher Gibson sold 50,000 shares of the business’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $7.73, for a total value of $386,500.00. Following the sale, the chief executive officer now owns 863,524 shares of the company’s stock, valued at $6,675,040.52. The disclosure for this sale can be found here. In the last ninety days, insiders sold 281,359 shares of company stock worth $2,410,876. 15.75% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Large investors have recently made changes to their positions in the company. Mubadala Investment Co PJSC bought a new stake in shares of Recursion Pharmaceuticals during the 4th quarter valued at about $128,041,000. Profund Advisors LLC lifted its position in shares of Recursion Pharmaceuticals by 209.0% during the 3rd quarter. Profund Advisors LLC now owns 184,235 shares of the company’s stock valued at $1,409,000 after buying an additional 124,621 shares in the last quarter. Citigroup Inc. lifted its position in shares of Recursion Pharmaceuticals by 165.3% during the 3rd quarter. Citigroup Inc. now owns 470,512 shares of the company’s stock valued at $3,599,000 after buying an additional 293,174 shares in the last quarter. Gladstone Institutional Advisory LLC purchased a new position in shares of Recursion Pharmaceuticals during the 4th quarter valued at about $133,000. Finally, Pathstone Family Office LLC purchased a new position in shares of Recursion Pharmaceuticals during the 3rd quarter valued at about $93,000. 89.06% of the stock is currently owned by institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.